Killip Classification

Bedside heart-failure severity in acute myocardial infarction
Clinical class
Tap the one that applies — its meaning opens right below.

About this score

When to use

Classifies acute myocardial infarction by bedside signs of heart failure: I none, II rales or third heart sound, III pulmonary oedema, IV cardiogenic shock. ⁦[1]⁩

Pearls and pitfalls

• The original 1967 series of 250 patients reported in-hospital mortality of about 6%, 17%, 38% and 81% for classes I–IV, before reperfusion therapy existed. ⁦[1, 2]⁩
• In a 2014 cohort, Killip class still predicted mortality up to five years after myocardial infarction, with a similar pattern in STEMI and NSTEMI. ⁦[2]⁩
Summarised from the numbered sources under Evidence. Check the source before relying on a statement.
Evidence
[1] Original publication
Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Classified acute MI by bedside heart-failure signs (I none, II rales/S3, III pulmonary oedema, IV cardiogenic shock); in-hospital mortality was roughly 6%, 17%, 38%, and 81%.
American Journal of Cardiology, 1967
Open source
[2] Validation
Mello BH, Oliveira GB, Ramos RF, et al. Validation of the Killip-Kimball classification and late mortality after acute myocardial infarction. Quotes the original 1967 in-hospital mortality (6%, 17%, 38%, 81%) and found the class still predicted mortality at a mean five-year follow-up in STEMI and NSTEMI.
Arquivos Brasileiros de Cardiologia, 2014
Open source
Last reviewed: 2026-10
Report an error in this calculator
MedScore is an educational and clinical decision-support tool. It does not provide a diagnosis, a treatment, or a drug-dosing recommendation, and it does not replace clinical judgement or local guidelines. Confirm every result against the original source before acting on it. The treating clinician remains responsible for all decisions.
Support the developer
MedScore is free on the web and made by a medical student. If it helps you, you can support its development.
Support MedScore